세계의 항균제 시장(2024-2034년)

The global Antibacterial Drug Market is projected to grow at a CAGR of 3.6% by 2034.

“The Antibacterial drugs Market Report 2024-2034”: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Difficulties in R&D

Antibacterial drug research and development has been impacted due to limited attractiveness of the market. Major factors that restrict entry of companies are low profit margins for short-course antibacterial treatment as compared to chronic disease drugs, limited marketing lifespan due to emerging resistance, availability of cheap generic drugs, necessary healthcare stewardship to limit antibacterial drug use. Hence, many public-private partnerships have been implemented with government, academia, and the pharmaceutical industry to provide financial and technical support for developing antibacterial drugs. According to WHO, there were only 27 new antibiotics in clinical development against priority pathogens in 2021 as compared 31 in 2017. In the preclinical stage, the number of products has remained constant over the last 3 years. Of the 27 antibiotics in clinical trial stage, only 6 fulfil at least one of WHO's criteria for innovation. The lack of innovation weakens the effectiveness of the limited number of new antibiotics.

Shortage of antibiotics

According to the US Pharmacopeia Medicine Supply Map Analysis, there is an increased shortage risk for antibiotics, supply chain risks that can lead to antimicrobial resistance. Antibiotics shortage is 42% more likely compared to all other drugs. The analysis is derived from 40 external datasets and proprietary information about the use of USP quality standards, covering 92% of generic medicines approved in the US. Antimicrobial shortage affects addressing the issue of AMR. As per the study, of all types of antibacterial drugs, cephalosporin are at elevated risk for shortage, driven by price. Additionally, 40% of active pharmaceutical ingredients (APIs) used for cephalosporin are currently in shortage. Furthermore, poor-quality medicines drive antimicrobial resistance (AMR) by exposing microorganisms in the body to sub-therapeutic doses of medicines. This leads to patient not receiving enough of the medication's active pharmaceutical ingredient (API), helping the pathogen to evolve and form more resistant strains can emerge.

Likewise, the European Commission, the Heads of Medicines Agencies (HMA), and the European Medicines Agency (EMA) issued recommendations in July 2023 to prevent shortages of antibiotics (e.g., amoxicillin, amoxicillin/clavulanic acid, penicillin, azithromycin, clarithromycin, ceftriaxone, cefotaxime and piperacillin-tazobactam) crucial in the treatment of respiratory infections. The recommendations were developed by the Executive Steering Group on Shortages and Safety in Medicinal Products (MSSG). EMA and the European Health Emergency Preparedness and Response Authority (HERA) will work with marketing authorization controllers to ensure first and second-line antibiotics for respiratory infections to match demand and avoid shortages.

What Questions Should You Ask before Buying a Market Research Report?

• How is the Antibacterial drugs market evolving?
• What is driving and restraining the Antibacterial drugs market?
• How will each antibacterial drug submarket segment grow during the forecast period and how much revenue will these submarkets account for in 2034?
• How will the market shares for each Antibacterial drugs submarket develop from 2024 to 2034?
• What will be the main driver for the overall market from 2024 to 2034?
• Will leading Antibacterial drugs markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
• Who are the leading players and what are their prospects over the forecast period?
• What are the Antibacterial drugs projects for these leading companies?
• How will the industry evolve during the period between 2024 and 2034? What are the implications of Antibacterial drugs projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the Antibacterial drugs market?
• Where is the Antibacterial drugs market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Antibacterial drugs market today, and over the next 10 years:

• Our 269-pages report provides 113 tables, 192 charts and graphs exclusively to you
• The report highlights key lucrative areas in the industry so you can target them - NOW
• It contains in-depth analysis of global, regional and national sales and growth
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the antibacterial drugs market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2034 and other analyses reveal commercial prospects

• In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares
• You will find original analyses, with business outlooks and developments
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Antibacterial drugs prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, ""V" ", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report:

Drug Class

• B-lactams
• Quinolones
• Macrolides
• Tetracyclines
• Aminoglycosides
• Sulfonamides
• Phenicols
• Other

Route of Administration

• Enteral
• Parenteral
• Other

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 20 leading national markets:

North America

• U.S
• Canada

Europe

• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific

Latin America

• Brazil
• Mexico
• Rest of Latin America

MEA

• GCC
• South Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Antibacterial Drugs Market, 2024 to 2034, with a focus on this segment of these companies' operations.

Leading companies profiled in the report:

Overall world revenue for Antibacterial drugs Market, 2024 to 2034 in terms of value the market will surpass US$ 39,178.7 million in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the “Antibacterial drugs Market, 2024 to 2034” report help you?

In summary, our 260-pages report provides you with the following knowledge:

• Revenue forecasts to 2034 for Antibacterial drugs Market, 2024 to 2034 Market, with forecasts for drug class, route of administration and distribution channel each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2034 for five regional and 20 key national markets - See forecasts for the Antibacterial drugs Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market - including company profiles for 10 of the major companies involved in the Antibacterial drugs Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Antibacterial drugs Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

• 1.1 Objectives of the Study
• 1.2 Introduction to Antibacterial drugs Market
• 1.3 What This Report Delivers
• 1.4 Why You Should Read This Report
• 1.5 Key Questions Answered By This Analytical Report Include:
• 1.6 Who is This Report For?
• 1.7 Methodology
  • 1.7.1 Market Definitions
  • 1.7.2 Market Evaluation & Forecasting Methodology
  • 1.7.3 Data Validation
• 1.8 Frequently Asked Questions (FAQs)
• 1.9 Associated Visiongain Reports
• 1.10 About Visiongain

2 Executive Summary

• 2.1 Geographical Snapshot: Global Antibacterial drugs Market
• 2.2 Drug Class Segment: Market Attractiveness Index
• 2.3 Route of Administration Segment: Market Attractiveness Index
• 2.4 Distribution Channel Segment: Market Attractiveness Index

3 Market Overview

• 3.1 Key Findings
• 3.2 Market Dynamics
  • 3.2.1 Market Driving Factors
  • 3.2.2 Market Restraining Factors
  • 3.2.3 Market Opportunities
  • 3.2.4 Challenges
• 3.3 COVID-19 Impact Analysis
• 3.4 Porter's Five Forces Analysis
  • 3.4.1 Supplier Power
  • 3.4.2 Buyer Power
  • 3.4.3 Competitive Rivalry
  • 3.4.4 Threat from Substitutes
  • 3.4.5 Threat of New Entrants

4 Global Antibacterial drugs Market Analysis by Drug Class

• 4.1 Key Findings
• 4.2 Drug class Segment Growth Prospects
• 4.3 Global Antibacterial drugs Market Size Estimation and Forecast by Drug Class
• 4.4 B-lactams
  • 4.4.1 B-lactams Market Forecast by Region, 2024-2034 (US$ Mn)
  • 4.4.2 B-lactams Market Share by Region, 2024-2034 (%)
• 4.5 Quinolones
  • 4.5.1 Quinolones Market Forecast by Region, 2024-2034 (US$ Mn)
  • 4.5.2 Quinolones Market Share by Region, 2024-2034 (%)
• 4.6 Macrolides
  • 4.6.1 Macrolides Market Forecast by Region, 2024-2034 (US$ Mn)
  • 4.6.2 Macrolides Market Share by Region, 2024-2034 (%)
• 4.7 Tetracycline
  • 4.7.1 Tetracycline Market Forecast by Region, 2024-2034 (US$ Mn)
  • 4.7.2 Tetracyclines Market Share by Region, 2024-2034 (%)
• 4.8 Aminoglycosides
  • 4.8.1 Aminoglycosides Market Forecast by Region, 2024-2034 (US$ Mn)
• 4.9 Sulfonamides
  • 4.9.1 Sulfonamides Market Forecast by Region, 2024-2034 (US$ Mn)
  • 4.9.2 Sulfonamides Market Share by Region, 2024-2034 (%)
• 4.10 Phenicols
  • 4.10.1 Phenicols Market Forecast by Region, 2024-2034 (US$ Mn)
  • 4.10.2 Phenicols Market Share by Region, 2024-2034 (%)
• 4.11 Other
  • 4.11.1 Other Market Forecast by Region, 2024-2034 (US$ Mn)
  • 4.11.2 Other Market Share by Region, 2024-2034 (%)

5 Global Antibacterial drugs Market Analysis by Route of Administration

• 5.1 Key Findings
• 5.2 Route of Administration Segment Growth Prospects
• 5.3 Global Antibacterial drugs Market Size Estimation and Forecast by Route of Administration
• 5.4 Global Antibacterial drugs Market Share by Route of Administration, 2024 & 2034
• 5.5 Enteral
  • 5.5.1 Enteral Market Forecast by Region, 2024-2034 (US$ Mn)
  • 5.5.2 Enteral Market Share by Region, 2024-2034 (%)
• 5.6 Parenteral
  • 5.6.1 Parenteral Market Forecast by Region, 2024-2034 (US$ Mn)
  • 5.6.2 Parenteral Market Share by Region, 2024-2034 (%)
• 5.7 Other RoA
  • 5.7.1 Other RoA Market Forecast by Region, 2024-2034 (US$ Mn)
  • 5.7.2 Other RoA Market Share by Region, 2024-2034 (%)

6 Global Antibacterial drugs Market Analysis by Distribution Channel

• 6.1 Key Findings
• 6.2 Distribution Channel Segment Growth Prospects
• 6.3 Global Antibacterial drugs Market Size Estimation and Forecast by Distribution Channel
• 6.4 Global Antibacterial drugs Market Share by Distribution Channel, 2023 & 2033
• 6.5 Hospital Pharmacies
  • 6.5.1 Hospital Pharmacies Market Forecast by Region, 2024-2034 (US$ Mn)
  • 6.5.2 Hospital Pharmacies Market Share by Region, 2024-2034 (%)
• 6.6 Retail Pharmacies
  • 6.6.1 Retail Pharmacies Market Forecast by Region, 2024-2034 (US$ Mn)
  • 6.6.2 Retail Pharmacies Market Share by Region, 2024-2034 (%)
• 6.7 Online Pharmacies
  • 6.7.1 Online Pharmacies Market Forecast by Region, 2024-2034 (US$ Mn)
  • 6.7.2 Online Pharmacies Market Share by Region, 2024-2034 (%)

7 Global Antibacterial drugs Market Analysis by Region

• 7.1 Key Findings
• 7.2 Regional Market Size Estimation and Forecast

8 North America Antibacterial drugs Market Analysis

• 8.1 Key Findings
• 8.2 North America Antibacterial drugs Market Attractiveness Index
• 8.3 North America Antibacterial drugs Market by Country, 2024, 2029 & 2034 (US$ Mn)
• 8.4 North America Antibacterial drugs Market Size Estimation and Forecast by Country
• 8.5 North America Antibacterial drugs Market Size Estimation and Forecast by Drug Class
• 8.6 North America Antibacterial drugs Market Size Estimation and Forecast by Route of Administration
• 8.7 North America Antibacterial drugs Market Size Estimation and Forecast by Distribution Channel
• 8.8 U.S.
  • 8.8.1 U.S. Antibacterial drugs Market by Drug Class
• 8.9 Canada
  • 8.9.1 Canada Antibacterial drugs Market by Drug Class

9 Europe Antibacterial drugs Market Analysis

• 9.1 Key Findings
• 9.2 Europe Antibacterial drugs Market Attractiveness Index
• 9.3 Europe Antibacterial drugs Market by Country, 2024, 2029 & 2034 (US$ Mn)
• 9.4 Europe Antibacterial drugs Market Size Estimation and Forecast by Country
• 9.5 Europe Antibacterial drugs Market Size Estimation and Forecast by Drug Class
• 9.6 Europe Antibacterial drugs Market Size Estimation and Forecast by Route of Administration
• 9.7 Europe Antibacterial drugs Market Size Estimation and Forecast by Distribution Channel
• 9.8 Germany
  • 9.8.1 Germany Antibacterial drugs Market by Drug Class
• 9.9 U.K.
  • 9.9.1 U.K. Antibacterial drugs Market by Drug Class
• 9.10 France
  • 9.10.1 France Antibacterial drugs Market by Drug Class
• 9.11 Italy
  • 9.11.1 Italy Antibacterial drugs Market by Drug Class
• 9.12 Spain
  • 9.12.1 Spain Antibacterial drugs Market by Drug Class
• 9.13 Rest of Europe
  • 9.13.1 Rest of Europe Antibacterial drugs Market by Drug Class

10 Asia Pacific Antibacterial drugs Market Analysis

• 10.1 Key Findings
• 10.2 Asia Pacific Antibacterial drugs Market Attractiveness Index
• 10.3 Asia Pacific Antibacterial drugs Market by Country, 2024, 2029 & 2034 (US$ Mn)
• 10.4 Asia Pacific Antibacterial drugs Market Size Estimation and Forecast by Country
• 10.5 Asia Pacific Antibacterial drugs Market Size Estimation and Forecast by Drug Class
• 10.6 Asia-Pacific Antibacterial drugs Market Size Estimation and Forecast by Route of Administration
• 10.7 Asia Pacific Antibacterial drugs Market Size Estimation and Forecast by Distribution Channel
• 10.8 Japan
  • 10.8.1 Japan Antibacterial drugs Market by Drug Class
• 10.9 China
  • 10.9.1 China Antibacterial drugs Market by Drug Class
• 10.10 India
  • 10.10.1 India Antibacterial drugs Market by Drug Class
• 10.11 South Korea
  • 10.11.1 South Korea Antibacterial drugs Market by Drug Class
• 10.12 Australia
  • 10.12.1 Australia Antibacterial drugs Market by Drug Class
• 10.13 Rest of APAC
  • 10.13.1 Rest of APAC Antibacterial drugs Market by Drug Class

11 Latin America Antibacterial drugs Market Analysis

• 11.1 Key Findings
• 11.2 Latin America Antibacterial drugs Market Attractiveness Index
• 11.3 Latin America Antibacterial drugs Market by Country, 2024, 2029 & 2034 (US$ Mn)
• 11.4 Latin America Antibacterial drugs Market Size Estimation and Forecast by Country
• 11.5 Latin America Antibacterial drugs Market Size Estimation and Forecast by Drug Class
• 11.6 Latin America Antibacterial drugs Market Size Estimation and Forecast by Route of Administration
• 11.7 Latin America Antibacterial drugs Market Size Estimation and Forecast by Distribution Channel
• 11.8 Brazil
  • 11.8.1 Brazil Antibacterial drugs Market by Drug Class
• 11.9 Mexico
  • 11.9.1 Mexico Antibacterial drugs Market by Drug Class
• 11.10 Rest of Latin America
  • 11.10.1 Rest of LATAM Antibacterial drugs Market by Drug Class

12 MEA Antibacterial drugs Market Analysis

• 12.1 Key Findings
• 12.2 MEA Antibacterial drugs Market Attractiveness Index
• 12.3 MEA Antibacterial drugs Market by Country, 2024, 2029 & 2034 (US$ Mn)
• 12.4 MEA Antibacterial drugs Market Size Estimation and Forecast by Country
• 12.5 MEA Antibacterial drugs Market Size Estimation and Forecast by Drug Class
• 12.6 MEA Antibacterial drugs Market Size Estimation and Forecast by Route of Administration
• 12.7 MEA Antibacterial drugs Market Size Estimation and Forecast by Distribution Channel
• 12.8 South Africa
  • 12.8.1 South Africa Antibacterial drugs Market by Drug Class
• 12.9 GCC
  • 12.9.1 GCC Antibacterial drugs Market by Drug Class
• 12.10 Rest of MEA
  • 12.10.1 Rest of MEA Antibacterial drugs Market by Drug Class

13 Competitive Landscape

• 13.1 Company Ranking Analysis
• 13.2 Key Business Strategy Analysis

14 Company Profiles

• 14.1 Pfizer
  • 14.1.1 Company Snapshot
  • 14.1.2 Company Overview
  • 14.1.3 Financial Analysis
  • 14.1.4 Product Benchmarking
  • 14.1.5 Strategic Outlook
• 14.2 Merck
  • 14.2.1 Company Snapshot
  • 14.2.2 Company Overview
  • 14.2.3 Financial Analysis
  • 14.2.4 Product Benchmarking
  • 14.2.5 Strategic Outlook
• 14.3 GSK
  • 14.3.1 Company Snapshot
  • 14.3.2 Company Overview
  • 14.3.3 Financial Analysis
  • 14.3.4 Product Benchmarking
  • 14.3.5 Strategic Outlook
• 14.4 AbbVie
  • 14.4.1 Company Snapshot
  • 14.4.2 Company Overview
  • 14.4.3 Financial Analysis
  • 14.4.4 Product Benchmarking
  • 14.4.5 Strategic Outlook
• 14.5 Bayer Pharmaceuticals
  • 14.5.1 Company Snapshot
  • 14.5.2 Company Overview
  • 14.5.3 Financial Analysis
  • 14.5.4 Product Benchmarking
  • 14.5.5 Strategic Outlook
• 14.6 Janssen Pharma (subsidiary of Johnson and Johnson)
  • 14.6.1 Company Snapshot
  • 14.6.2 Company Overview
  • 14.6.3 Financial Analysis
  • 14.6.4 Product Benchmarking
  • 14.6.5 Strategic Outlook
• 14.7 AstraZeneca
  • 14.7.1 Company Snapshot
  • 14.7.2 Company Overview
  • 14.7.3 Financial Analysis
  • 14.7.4 Product Benchmarking
  • 14.7.5 Strategic Outlook
• 14.8 Novartis
  • 14.8.1 Company Snapshot
  • 14.8.2 Company Overview
  • 14.8.3 Financial Analysis
  • 14.8.4 Product Benchmarking
  • 14.8.5 Strategic Outlook
• 14.9 Bristol-Myers Squibb Company
  • 14.9.1 Company Snapshot
  • 14.9.2 Company Overview
  • 14.9.3 Financial Analysis
  • 14.9.4 Product Benchmarking
  • 14.9.5 Strategic Outlook
• 14.10 Sanofi
  • 14.10.1 Company Snapshot
  • 14.10.2 Company Overview
  • 14.10.3 Financial Analysis
  • 14.10.4 Product Benchmarking
  • 14.10.5 Strategic Outlook

15 Conclusion and Recommendations

• 15.1 Final findings of report
• 15.2 Recommendations for Market Players